Hengrui Pharma(SH:600276) Xin Lang Cai Jing·2025-09-30 10:34Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by Sun Jie, a senior vice president of Heng Rui Medicine, indicating a strategic move in the company's shareholding structure [1][3]. Shareholding Situation Before Reduction - Before the reduction, Sun Jie held 1,907,032 shares, representing 0.029% of the company's total share capital. The shares were acquired through equity incentives (1,883,032 shares) and other means (24,000 shares) [2]. Reduction Plan and Implementation Results - On June 16, 2025, Heng Rui Medicine disclosed Sun Jie's plan to reduce his holdings by up to 476,700 shares within three months, excluding a window period. The maximum reduction would account for 25% of his holdings and 0.007% of the total share capital [3]. - As of September 30, 2025, the reduction plan was completed, with Sun Jie having reduced his holdings by 237,040 shares, which is 0.004% of the total share capital. The reduction occurred between July 9 and September 25, 2025, through centralized bidding, with share prices ranging from 57.01 to 73.95 yuan per share, totaling approximately 15.63 million yuan [3]. - Following the reduction, Sun Jie now holds 1,669,992 shares, decreasing his ownership percentage to 0.025%. The actual reduction aligns with the previously disclosed plan and commitments [3].